Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ethambutol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.94 |
| ▸ | CNR1 | P21554 | 1/20 | 0.94 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.94 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.94 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethambutol SCHEMBL3398 | 1.00 | ABCC3 (1.00) | ABCC3SMN1; SMN2LMNACNR1ADRA1A | |
| Ethambutol SCHEMBL27583822 | 1.00 | ABCC3 (1.00) | ABCC3SMN1; SMN2LMNACNR1ADRA1A | |
| Ethambutol SCHEMBL3026481 | 1.00 | ABCC3 (1.00) | ABCC3SMN1; SMN2LMNACNR1ADRA1A | |
| Ethambutol SCHEMBL3400 | 1.00 | ABCC3 (1.00) | ABCC3SMN1; SMN2LMNACNR1ADRA1A | |
| Ethambutol SCHEMBL37049 | 1.00 | ABCC3 (1.00) | ABCC3SMN1; SMN2LMNACNR1ADRA1A | |
| Ethambutol SCHEMBL9949005 | 1.00 | ABCC3 (1.00) | ABCC3SMN1; SMN2LMNACNR1ADRA1A | |
| Ethambutol SCHEMBL2636850 | 0.97 | LMNA (1.00) | ABCC3SMN1; SMN2LMNACNR1ADRA1A | |
| Ethambutol SCHEMBL15479016 | 0.97 | LMNA (1.00) | ABCC3SMN1; SMN2LMNACNR1ADRA1A | |
| Ethambutol SCHEMBL3399 | 0.97 | LMNA (1.00) | ABCC3SMN1; SMN2LMNACNR1ADRA1A | |
| Ethambutol SCHEMBL2961583 | 0.97 | LMNA (1.00) | ABCC3SMN1; SMN2LMNACNR1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20230414584-A1 | ADMINISTRATION OF ANTIBIOTIC COMPOUNDS FOR THE TREATMENT OF STREPTOCOCCAL INFECTIONS FOR THE TREATMENT OF PSORIASIS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2023-12-28 | — | — | US | claimed |
| CN-116650492-A | Administration of antibiotic compounds for the treatment of streptococcal infections to treat psoriasis | 消化系统疾病中心 | 2023-08-29 | — | — | CN | claimed |
| WO-2015009879-A1 | COMPOSITIONS FOR MODULATING NRF2-ARE ACTIVITY AND THEIR METHODS OF USE | THE HAMNER INSTITUTES (US) | 2015-01-22 | — | — | WO | claimed |
| EP-1996217-B1 | NOVEL ANTIBIOTIC COMPOSITIONS | CAMBRIDGE ENTPR LTD (GB) | 2010-11-10 | — | — | EP | claimed |
| US-20100221245-A1 | TOPICAL SKIN CARE COMPOSITION | DERMADOCTOR, LLC | 2010-09-02 | — | — | US | claimed |
| US-4720456-A | Trehalose lipid tetraesters | WINTERSHALL AG (DE) | 1988-01-19 | — | — | US | claimed |
| EP-4743069-A1 | STABLE SOLID DISPERSIONS OF SALCAPROZATE WITH VARIOUS ACTIVE PHARMACEUTICAL INGREDIENTS | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2026-05-20 | — | — | EP | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| EP-4698568-A1 | PARTICLES OF HYDROPHOBIC-CHAIN-MODIFIED MONOSACCHARIDES AND CYCLODEXTRIN | Paris Sciences et Lettres (FR) | 2026-02-25 | — | — | EP | disclosed |
| US-20260027191-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | UNIV ARIZONA (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4628100-A2 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | Gregg, John Malcolm Hall (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12343361-B2 | Compositions and methods for the treatment of hepatic diseases and disorders | LABYRINTH HOLDINGS, LLC (US) | 2025-07-01 | — | — | US | disclosed |
| CN-1201739-C | Medicine-release system of compound Rifampicin | GAO HUAN (CN) | 2005-05-18 | — | — | CN | disclosed |
| WO-2004054500-A2 | PREPARATION OF SUBMICRON SIZED PARTICLES WITH POLYMORPH CONTROL AND NEW POLYMORPH OF ITRACONAZOLE | BAXTER INTERNATIONAL INC. (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20030096013-A1 | Preparation of submicron sized particles with polymorph control | BAXTER INTERNATIONAL INC. | 2003-05-22 | — | — | US | disclosed |
| US-6372752-B1 | ENZYME INHIBITORS, RESPIRATORY SYSTEM DISORDERS, TUBERCULOSIS AND MYCOBACTERIUM BACTERICIDES | GENZYME CORPORATION | 2002-04-16 | — | — | US | disclosed |
| WO-2001056974-A2 | INHA INHIBITORS AND THEIR USE AS ANTIBACTERIALS | GENZYME CORPORATION (US) | 2001-08-09 | — | — | WO | disclosed |
| US-4720456-A | Trehalose lipid tetraesters | WINTERSHALL AG (DE) | 1988-01-19 | — | — | US | disclosed |
| US-3944616-A | Purification of d,d'-2,2'(ethylenediimino)di-1-butanol dihydrochloride | AMERICAN CYANAMID COMPANY (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027191-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | DNMT3L, DNMT3A, DNMT1 | ABCC3 1668/4885SMN1; SMN2 2629/4885LMNA 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.